SERUM S100 PROTEINS AS A MARKER OF DISEASE ACTIVITY IN LARGE VESSEL VASULITIS
Issue Date
2015-12-31Author
Springer, Jason Michael
Publisher
University of Kansas
Format
20 pages
Type
Thesis
Degree Level
M.S.
Discipline
Preventive Medicine and Public Health
Rights
Copyright held by the author.
Metadata
Show full item recordAbstract
Objectives: Serum S100A8/S100A9 and S100A12 levels have been shown to be elevated in giant cell arteritis (GCA). This study aimed to determine if levels of serum S100 proteins perform as markers in a comparable fashion to standard markers of disease activity in large-vessel vasculitis. Methods: Serum samples were obtained from the Vasculitis Clinical Research Consortium (VCRC) Longitudinal Study of GCA and Takayasu’s arteritis (TAK). A mixed effects model compared S100 proteins during active and inactive disease states. Receiver operating characteristic curves compared models using S100 proteins to models using ESR and CRP. Results: There were 106 samples (50 during active disease) from patients with GCA and 32 samples (16 during active disease) from patients with TAK. In GCA, S100A8/S100A9 and S100A12 were significantly elevated during active disease (2150 ng/mL vs. 2020 ng/mL, p = 0.003;150 ng/mL vs. 130ng/mL, p=0.016, respectively). There were weak correlations between levels of S100 proteins and ESR or CRP. A model including S100A8/S100A9, S100A12, ESR, and CRP was a better indicator of disease activity compared to ESR and CRP together. In TAK, there were no significant differences between active and inactive disease for either the S100 proteins or ESR/CRP. Conclusions: Serum levels of S100A8/S100A9 and S100A12 are elevated during active disease and perform comparably to ESR and CRP as measures of disease activity in giant cell arteritis.
Collections
- KU Med Center Dissertations and Theses [464]
- Theses [3906]
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.